The Benefit of Quality Control Charts (QCC) for Routine Quantitative BCR-ABL1 Monitoring in Chronic Myeloid Leukemia

PLoS ONE - United States
doi 10.1371/journal.pone.0196326
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Clinical and Prognostic Significance of E1a2 BCR-ABL1 Transcript Subtype in Chronic Myeloid Leukemia

Blood Cancer Journal
OncologyHematology
2017English

Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia

Molecular Therapy - Nucleic Acids
Drug DiscoveryMolecular Medicine
2017English

Genomic BCR-ABL1 Breakpoint Characterization by a Multi-Strategy Approach for �personalized Monitoring� of Residual Disease in Chronic Myeloid Leukemia Patients

Oncotarget
Oncology
2018English

Combined STAT3 and BCR-ABL1 Inhibition Induces Synthetic Lethality in Therapy-Resistant Chronic Myeloid Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2014English

Requirement of SRC Kinases Lyn, HCK and FGR for BCR-ABL1-induced B-Lymphoblastic Leukemia but Not Chronic Myeloid Leukemia

Nature Genetics
Genetics
2004English

The Impact of BCR-ABL1 Transcript Type on Tyrosine Kinase Inhibitor Responses and Outcomes in Patients With Chronic Myeloid Leukemia

Cancer
Cancer ResearchOncology
2018English

A Novel BCR-ABL1 Fusion Gene With Genetic Heterogeneity Indicates a Good Prognosis in a Chronic Myeloid Leukemia Case

Molecular Cytogenetics
BiochemistryMolecular MedicineGeneticsMolecular Biology
2017English

Immune Control in Chronic Myeloid Leukemia

Oncotarget
Oncology
2017English

New Tool for Monitoring Molecular Response in Chronic Myeloid Leukemia.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy